Literature DB >> 17497289

The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.

Gaopeng Li1, Xiaoping Chen, Qi Wang, Zongquan Xu, Wanguang Zhang, Lu Ye.   

Abstract

The roles of multi-drug resistance protein 1 (MDR1), multi-drug resistance related protein 1 (MRP1), lung resistance protein (LRP) and breast cancer resistance protein (BCRP) in the multi-drug resistance (MDR) of hepatocellular carcinoma (HCC) were studied. By exposing HepG2 cell line to progressively increased concentrations of adriamycin (ADM), HepG2 multi-drug resistant subline (HepG2/ADM) was induced. The MDR index of HepG2/ADM was detected by using MTT. The expressions of the four MDR proteins in the three cell lines (L02, HepG2, HepG2/ADM) were investigated at mRNA and protein levels by real-time RT-PCR and Western blot respectively. Our results showed that when the ADM concentration was under 100 microg/L, HepG2 could easily be induced to be drug-resistant. The IC(50) of the HepG2/ADM to ADM was 282 times that of HepG2. The expression of MDR1 and BCRP mRNA in HepG2/ADM cells were 400 and 9 times that of HepG2 cells respectively while there was no difference in the mRNA expressions of MRP1 and LRP. There was no difference between HepG2 and L02 cells in the mRNA expressions of the four genes. At the protein level, the expressions of MDR1, BCRP and LRP but MRP1 in HepG2/ADM were significantly higher than those of HepG2 and L02. Between HepG2 and L02, there was no difference in the expressions of four genes at the protein level. HepG2/ADM is a good model for the study of MDR. The four genes are probably the normally expressed gene in liver. The expressions of MDR1 and BCRP could be up-regulated by anti-cancer agents in vitro. The MDR of HCC was mainly due to the up-regulation of MDR1 and BCRP but MRP1 and LRP. These findings suggest they may serve as targets for the reversal of MDR of HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497289     DOI: 10.1007/s11596-007-0217-8

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  11 in total

1.  A multidrug resistance transporter from human MCF-7 breast cancer cells.

Authors:  L A Doyle; W Yang; L V Abruzzo; T Krogmann; Y Gao; A K Rishi; D D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

2.  [Study on the mechanism of reversing multidrug resistance of hepatocarcinoma by bromocriptine].

Authors:  Lei Ding; Xiao-ping Chen; Zhi-wei Zhang; Wan-guang Zhang; Bin Cao; Zhi-hui Wang; Chun-lei Li
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2006-05

3.  Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.

Authors:  Gracia Merino; Antonius E van Herwaarden; Els Wagenaar; Johan W Jonker; Alfred H Schinkel
Journal:  Mol Pharmacol       Date:  2005-02-18       Impact factor: 4.436

4.  Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.

Authors:  Dorina M van der Kolk; Edo Vellenga; George L Scheffer; Michael Müller; Susan E Bates; Rik J Scheper; Elisabeth G E de Vries
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

5.  P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.

Authors:  Harunobu Tahara; Hiroyuki Kusuhara; Eiichi Fuse; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2005-04-08       Impact factor: 3.922

6.  Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.

Authors:  Erin L Volk; Kate M Farley; Yan Wu; Fei Li; Robert W Robey; Erasmus Schneider
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

7.  Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.

Authors:  A Suvannasankha; H Minderman; K L O'Loughlin; T Nakanishi; W R Greco; D D Ross; M R Baer
Journal:  Leukemia       Date:  2004-07       Impact factor: 11.528

8.  Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations.

Authors:  Dorothee Brügger; Klaus Brischwein; Chao Liu; Peter Bader; Dietrich Niethammer; Volker Gekeler; James F Beck
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

9.  Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.

Authors:  Petra Kowalski; Ulrike Stein; George L Scheffer; Hermann Lage
Journal:  Cancer Gene Ther       Date:  2002-07       Impact factor: 5.987

10.  Low levels of ABCG2 expression in adult AML blast samples.

Authors:  Brian L Abbott; Anne-Marie Colapietro; Yuxiao Barnes; Frank Marini; Michael Andreeff; Brian P Sorrentino
Journal:  Blood       Date:  2002-07-25       Impact factor: 22.113

View more
  9 in total

Review 1.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

2.  Recent insights into hepatic cancer stem cells.

Authors:  Beatrice Anfuso; Claudio Tiribelli; Caecilia H C Sukowati
Journal:  Hepatol Int       Date:  2013-12-20       Impact factor: 6.047

3.  Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro.

Authors:  Sebastian Buschauer; Andreas Koch; Philipp Wiggermann; Martina Müller; Claus Hellerbrand
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

4.  The cooperative effect of p53 and Rb in local nanotherapy in a rabbit VX2 model of hepatocellular carcinoma.

Authors:  Shengli Dong; Qibin Tang; Miaoyun Long; Jian Guan; Lu Ye; Gaopeng Li
Journal:  Int J Nanomedicine       Date:  2013-10-02

5.  BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.

Authors:  Wei-Chien Huang; Yi-Ling Hsieh; Chao-Ming Hung; Pei-Hsuan Chien; Yu-Fong Chien; Lei-Chin Chen; Chih-Yen Tu; Chia-Hung Chen; Sheng-Chieh Hsu; Yueh-Ming Lin; Yun-Ju Chen
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

6.  Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.

Authors:  Chunlei Wang; Xiaoyan Wei; Guoliang Shao
Journal:  Med Sci Monit       Date:  2021-02-01

7.  Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.

Authors:  Caecilia Hc Sukowati; Natalia Rosso; Devis Pascut; Beatrice Anfuso; Giuliano Torre; Paola Francalanci; Lory S Crocè; Claudio Tiribelli
Journal:  BMC Gastroenterol       Date:  2012-11-15       Impact factor: 3.067

8.  Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU.

Authors:  Bo Tang; Zhigao Hu; Yang Li; Shengguang Yuan; Zhenran Wang; Shuiping Yu; Songqing He
Journal:  Mol Med Rep       Date:  2015-11-06       Impact factor: 2.952

9.  Synergism of wt-p53 and synthetic material in local nano-TAE gene therapy of hepatoma: comparison of four systems and the possible mechanism.

Authors:  Gaopeng Li; Wenqin Kang; Mingliang Jin; Lidong Zhang; Jian Zheng; Kai Jia; Jinfeng Ma; Ting Liu; Xueyi Dang; Zhifeng Yan; Zefeng Gao; Jun Xu
Journal:  BMC Cancer       Date:  2019-11-20       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.